0534U CPT® code: payer coverage and prior authorization0534U appears in 5 coverage policies from Aetna, Blue Cross & Blue Shield of Mississippi, Blue Cross NC, Regence, UnitedHealthcare.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Aetna | Genetic Testing (0140) Frizzled class receptor 6 (FZD6) gene sequencing, Glomerulopathy gene set | not covered | Aug 18, 2026 | payer document |
| Blue Cross & Blue Shield of Mississippi | Genetic And Protein Biomarkers For The Diagnosis And Cancer Risk Assessment Of Prostate Cancer | unproven / investigational | payer document | |
| Blue Cross NC | Gene Expression Profiling and Protein Biomarkers for Prostate Cancer AHS - M2166 | listed, no stance | Apr 1, 2026 | payer document |
| Regence | Gene-Based Tests for Screening, Detection, and Management of Prostate or Bladder Cancer (Genetic Testing 17) | listed, no stance | Nov 1, 2025 | payer document |
| UnitedHealthcare | Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions (2026T0588QQ) | listed, no stance | Aug 1, 2026 | payer document |
Prior authorization required or conditional in IN, MS.
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.